Abstract: SA-PO266

The Cure Glomerulonephropathy (CureGN) IgA Nephropathy and IgA Vasculitis Cohort

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders

Authors

  • Selewski, David T., University of Michigan, Ann Arbor, Michigan, United States
  • Julian, Bruce A., University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Lafayette, Richard A., Stanford University, Stanford, California, United States
  • Nachman, Patrick H., University of North Carolina School of Medicine , Chapel Hill, North Carolina, United States
  • Nast, Cynthia C., Cedars-Sinai Medical Center, Los Angeles, California, United States
  • Novak, Jan, University of Alabama at Birmingham, Birmingham, Alabama, United States
  • O'Shaughnessy, Michelle M., Stanford University Medical Center, Palo Alto, California, United States
  • Palmer, Matthew, University of Pennsylvania , Philadelphia, Pennsylvania, United States
  • Reich, Heather N., Toronto General Hospital, Toronto, Ontario, Canada
  • Rizk, Dana, University of Alabama, Birmingham, Alabama, United States
  • Robinson, Bruce M., Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Ambruzs, Josephine M., Arkana Laboratories, Little Rock, Arkansas, United States
  • Sanghani, Neil S., Vanderbilt Nephrology, Nashville, Tennessee, United States
  • Sexton, Melissa, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Sperati, John, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
  • Zee, Jarcy, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Kiryluk, Krzysztof, Columbia University, New York, New York, United States
  • Appel, Gerald B., Columbia University College of Physicians and Surgeons, Scarsdale, New York, United States
  • Bomback, Andrew S., Columbia University, New York, New York, United States
  • Cattran, Daniel C., Toronto General Hospital, Toronto, Ontario, Canada
  • Fava, Melissa, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Gillespie, Brenda W., University of Michigan, Ann Arbor, Michigan, United States
  • Helmuth, Margaret, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States
  • Hogan, Jonathan J., Hospital of the University of Pennsylvania , Philadelphia, Pennsylvania, United States

Group or Team Name

  • On behalf of the CureGN IgA writing group
Background

Cure Glomerulonephropathy (CureGN) is a multi-center(66 sites), NIDDK-funded longitudinal observational cohort study of 2400 prevalent (biopsy within 5 years) patients with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy (IgAN), including IgA vasculitis (IgAV, previously referred to as Henoch-Schonlein Purpura). We present enrollment data for the fully enrolled IgAN/IgAV cohort comparing children and adults.

Methods

Study data of 590 patients with biopsy confirmed IgAN or IgAV were reviewed. Lab and treatment data up to the time of enrollment are shown using descriptive statistics and univariate tests. We analyzed data to compare adults and children with IgAN and IgAV. Data are presented as median(IQR) and N(%).

Results

A total of 590 patients (355 adult and 235 pediatric) are in the IgAN/IgAV cohort. A comparison of adult to pediatric patients with IgAN and IgAV is in Table 1. Adults had lower eGFR at both time-points and lower enrollment albumin. For IgAN, adults had more proteinuria at both time-points. Patients with IgAV received more immunosuppression (83%v53%, p<0.001) and corticosteroids (81%v50%, p<0.001). 30% of children and 28% of adults with IgAV received either cyclophosphamide or mycophenolate mofetil.

Conclusion

This study reveals significant differences in the disease presentation and early disease course between children and adults with IgAV and IgAN. Furthermore, there were significant differences in treatments between IgAV and IgAN. This is the largest North American prospective IgAN/IgAV cohort initiated to date and will serve as an important resource to answer pathobiology questions in the future.

Table 1: Comparison of IgA Nephropathy and igA Vasculitis between Children and Adults

Funding

  • NIDDK Support